The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...
Lung cancer is the most common primary tumor associated with brain metastases. Currently, the molecular mechanisms underlying the pathogenesis of lung cancer brain metastasis (LCBM) have not been ...
About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan ...
Gerard Silvestri, M.D., left and Adam Fox, M.D., began looking at how many people with metastatic non-small-cell lung cancer receive systemic treatment after wondering how many undergo biomarker ...
Bengaluru: Pfizer said its drug for a type of lung cancer missed the main goal of improving survival in patients ...
Genomic data should be considered when selecting patients with metastatic NSCLC for MDT, and these results provide evidence that integrating multimodal data to number of metastases may better identify ...
Pfizer Inc. PFE on Monday reported mixed topline results from its Phase 3 SigVie-002 trial of investigational antibody-drug ...
Please provide your email address to receive an email when new articles are posted on . Less than half of older adults with metastatic lung cancer received systemic treatment. Findings underscore the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results